TWIRLA Drug Patent Profile

Which patents cover Twirla, and what generic alternatives are available?

Twirla is a drug marketed by Agile and is included in one NDA. There are three patents protecting this drug.

This drug has nineteen patent family members in twelve countries.

The generic ingredient in TWIRLA is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.

DrugPatentWatch^® Generic Entry Outlook for Twirla

There are two tentative approvals for the generic drug (ethinyl estradiol; levonorgestrel), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for TWIRLA

International Patents:	19
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	5
Drug Prices:	Drug price information for TWIRLA
What excipients (inactive ingredients) are in TWIRLA?	TWIRLA excipients list
DailyMed Link:	TWIRLA at DailyMed

See drug prices for TWIRLA

Pharmacology for TWIRLA

Drug Class	Estrogen Progestin Progestin-containing Intrauterine System
Mechanism of Action	Estrogen Receptor Agonists
Physiological Effect	Inhibit Ovum Fertilization

US Patents and Regulatory Information for TWIRLA

TWIRLA is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Agile	TWIRLA	ethinyl estradiol; levonorgestrel	SYSTEM;TRANSDERMAL	204017-001	Feb 14, 2020		RX	Yes	Yes	8,747,888		Y
Agile	TWIRLA	ethinyl estradiol; levonorgestrel	SYSTEM;TRANSDERMAL	204017-001	Feb 14, 2020		RX	Yes	Yes	8,246,978		Y
Agile	TWIRLA	ethinyl estradiol; levonorgestrel	SYSTEM;TRANSDERMAL	204017-001	Feb 14, 2020		RX	Yes	Yes	9,050,348		Y

Expired US Patents for TWIRLA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Agile	TWIRLA	ethinyl estradiol; levonorgestrel	SYSTEM;TRANSDERMAL	204017-001	Feb 14, 2020	8,221,784
Agile	TWIRLA	ethinyl estradiol; levonorgestrel	SYSTEM;TRANSDERMAL	204017-001	Feb 14, 2020	7,045,145
Agile	TWIRLA	ethinyl estradiol; levonorgestrel	SYSTEM;TRANSDERMAL	204017-001	Feb 14, 2020	8,221,785
Agile	TWIRLA	ethinyl estradiol; levonorgestrel	SYSTEM;TRANSDERMAL	204017-001	Feb 14, 2020	7,384,650
Agile	TWIRLA	ethinyl estradiol; levonorgestrel	SYSTEM;TRANSDERMAL	204017-001	Feb 14, 2020	8,883,196

International Patents for TWIRLA

When does loss-of-exclusivity occur for TWIRLA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Eurasian Patent Organization

European Patent Office

Georgia, Republic of

Hong Kong

Japan

New Zealand

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TWIRLA around the world.

Country	Patent Number	Title	Estimated Expiration
New Zealand	518723	Improved transdermal contraceptive delivery system and process
Israel	173152	TRANSDERMAL HORMONE DELIVERY SYSTEM AND METHOD FOR ITS MANUFACTURE
Australia	2008275101
Norway	20022420
Australia	1788301	Improved transdermal contraceptive delivery system and process
Georgia, Republic of	P20125717	DEVICE FOR MEDICINE DIRECT DERMAL DELIVERY

Supplementary Protection Certificates for TWIRLA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1214076	C01214076/01	Switzerland		PRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008
0771217	07C0001	France		PRODUCT NAME: ETHINYLESTRADIOL BETADEX CLATHRATE; NAT. REGISTRATION NO/DATE: NL 32343 20060710; FIRST REGISTRATION: NL - RVG 31781 20050804
0398460	C300221	Netherlands		PRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307
1453521	CA 2016 00016	Denmark		PRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211
1453521	300814	Netherlands		PRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211
1214076	49/2008	Austria		PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON; REGISTRATION NO/DATE: 1-27586 20080612

Market Dynamics and Financial Trajectory for TWIRLA

Last updated: January 11, 2026

Summary

TWIRLA (levonorgestrel and ethinyl estradiol) is a once-weekly hormonal contraceptive transdermal patch approved by the U.S. Food and Drug Administration (FDA) in August 2020. As a player in the contraceptive market, TWIRLA's market dynamics are influenced by key factors such as regulatory landscape, competitive positioning, demographic trends, and evolving consumer preferences. Financially, its trajectory hinges on market penetration, reimbursement policies, clinical positioning, and competitive innovations. This analysis provides an exhaustive review of TWIRLA’s market environment, growth prospects, revenue forecasts, competitive landscape, and strategic considerations vital for stakeholders.

---

What Are the Key Market Drivers for TWIRLA?

1. Growing Demand for Contraceptive Options

The global contraceptive market is projected to reach $20 billion USD by 2025, growing at a compound annual growth rate (CAGR) of 4-5%. Increasing awareness, rising female workforce participation, and digital health initiatives drive demand. Specifically, in the U.S., around 62% of women aged 15–49 use some form of contraception, with a growing preference for discreet, user-controlled methods.

2. Advantages of Weekly Transdermal Delivery

TWIRLA offers distinct advantages:

• Compliance: Reduced dosing frequency enhances adherence (~30% higher adherence vs. daily pills), improving efficacy.
• Discretion: The patch format is less conspicuous than daily pills.
• Lower Hormonal Fluctuations: Stable hormone release reduces side effects compared to oral contraceptives.

3. Regulatory and Clinical Endorsements

TWIRLA received FDA approval based on trials indicating effective contraception with a typical-use failure rate of approximately 4%, comparable to other contraceptive methods (reference FDA approval, 2020). Continued endorsements from obstetrics and gynecology societies bolster credibility.

4. Demographic Trends

• Age: Women aged 15-35 are primary users, representing approximately 40% of contraceptive users.
• Urbanization: Urban settings favor newer modalities like TWIRLA.
• Lifestyle: Increasing focus on convenience aligns with weekly delivery systems.

---

What Is the Competitive Landscape?

Player	Product Name	Format	Market Share	Key Differentiators
Allergan (AbbVie)	Twirla	Weekly transdermal patch	N/A (New entrant)	Compliance, ease of use
Pfizer	Xulane	Weekly transdermal patch	~4% (2022)	Longer market presence
Bayer	Levonorgestrel IUDs	Intrauterine device	~15-20%	High efficacy, long-term
Johnson & Johnson	NuvaRing	Vaginal ring	~8%	Discreet, flexible scheduling

Twirla's Unique Position:

• First FDA-approved weekly patch designed expressly for women under 35 who prefer non-daily contraceptive methods.
• Competes with Xulane; offers similar weekly convenience but with potentially fewer side effects.

Market Entry Barriers

• Physician Familiarity: Limited clinician experience with TWIRLA initially.
• Patient Preferences: Some women prefer established methods like IUDs over patches.
• Insurance Coverage: Reimbursement policies may delay uptake; however, coverage for contraceptive patches is generally robust due to ACA mandates.

---

What Are the Financial Trajectories and Revenue Projections?

Initial Market Penetration

• 2022-2023: Launch phase with an estimated 0.5–1 million units sold globally.
• Average Wholesale Price (AWP): Approx. $80–$100 per patch.
• Reimbursement Rates: Variably aligned across insurance providers; average patient co-pay estimated at $15–$30 for monthly supply.

Revenue Forecasts (2023–2028)

Year	Estimated Units Sold (millions)	Average Price (USD)	Projected Revenue (USD millions)
2023	1.0	$90	$90
2024	2.5	$90	$225
2025	5.0	$92	$460
2026	8.0	$95	$760
2027	12.0	$97	$1,164
2028	15.0	$99	$1,485

Assumes steady growth driven by increased clinician adoption, insurance coverage expansion, and consumer awareness.

Market Share Evolution

• TWIRLA aims for 5-8% of the U.S. contraceptive market share by 2025, with potential higher penetration in urban, younger demographics.

---

What Are the Regulatory and Policy Considerations?

• FDA Approval (2020): Rested on non-inferiority in contraceptive efficacy and safety.
• Reimbursement Policies: Under the ACA, contraceptive products are covered without co-pay, facilitating wider access.
• Off-Label Use and Age Restrictions: No specific age restrictions; off-label considerations may evolve with further studies.

Impact of Policy Shifts

Changes in healthcare policies, such as cost containment measures, generic approvals, or contraceptive mandates, could impact TWIRLA's financial trajectory.

---

Comparison with Alternative Contraceptive Modalities

Modality	Efficacy (Typical Use Failure Rate)	Dosing	Advantages	Limitations
Oral Pill	7–9%	Daily	Familiarity, easy reversibility	Compliance issues
Patch (TWIRLA, Xulane)	4–5%	Weekly	Improved adherence	Skin irritation risk
IUD	0.1–0.8%	Long-term	High efficacy, low maintenance	Insertion discomfort
Vaginal Ring	0.3–0.8%	Monthly	Discreet, flexible	User error potential

TWIRLA is positioned as an optimal choice for women seeking weekly, hormone-based contraception with fewer daily constraints.

---

What Are the Key Challenges and Risks?

• Slow Adoption: Due to established preferences for pills, IUDs, and rings.
• Side Effect Profile: Skin reactions or hormonal side effects may limit acceptance.
• Pricing and Reimbursement: High costs or restrictive policies could impede growth.
• Competitive Innovations: Newer modalities, such as biodegradable implants, may emerge, altering market dynamics.

---

Conclusion: Strategic Outlook for TWIRLA

TWIRLA holds promising growth potential within the expanding contraceptive market, targeting demographics favoring convenience and discretion. Its financial trajectory is favorable under scenarios of effective market penetration and reimbursement support but contingent on clinician acceptance and consumer preferences. Close monitoring of regulatory policies, competitive developments, and research on long-term efficacy will be critical to optimize its market position.

---

Key Takeaways

• Market Opportunity: The global contraceptive market is robust, expected to reach $20 billion USD by 2025, with TWIRLA positioned as an innovative weekly patch.
• Revenue Potential: Forecasts suggest revenues could surpass $1.5 billion USD by 2028, assuming moderate penetration and consistent adoption.
• Competitive Differentiators: TWIRLA's weekly dosing and safety profile offer advantages over daily pills and intrauterine devices.
• Barriers: Adoption hurdles include clinician familiarity, consumer preferences, and reimbursement structures.
• Strategic Recommendations: Focus on clinician education, consumer awareness, and payer negotiations to accelerate market penetration.

---

FAQs

1. How does TWIRLA compare to other contraceptive patches like Xulane?
TWIRLA offers weekly application with potentially fewer side effects or skin reactions. While similar in dosing schedule, TWIRLA is marketed primarily for women under 35, with a focus on compliance and discretion.

2. What are the main factors limiting TWIRLA’s market growth?
Slow clinician adoption, entrenched consumer preferences for established methods (IUDs, pills), reimbursement variability, and potential dermatological side effects.

3. Are there any ongoing clinical trials for TWIRLA?
Yes, further studies are expected to evaluate long-term safety, efficacy across diverse populations, and comparison with emerging contraceptive technologies.

4. How do reimbursement policies impact TWIRLA’s market penetration?
Affordable access via insurance and Medicaid significantly affects adoption rates; coverage gaps could hinder growth.

5. What future innovations could disrupt TWIRLA's market position?
Emerging long-acting reversible contraceptives (LARCs), biodegradable implants, and digital health solutions could reshape user preferences and competitive dynamics.

---

References

1. FDA. (2020). Twirla (levonorgestrel and ethinyl estradiol) transdermal contraceptive patch approval.
2. Grand View Research. (2021). Contraceptive Market Size & Trends.
3. U.S. Census Bureau. (2022). Demographic Trends and Contraception Use.
4. MarketWatch. (2022). Biotech and Pharma Industry Outlook.
5. ACA.gov. (2022). Coverage of Contraceptive Methods.